Pharmasset Inc. (fka VRUS)

[oc631]

Analyst Upgrade- PSI-7977





Considering that Citi's analyst tripled his price target I suspect he overlooked the angle on the GT2/GT3 population. A launch date of 2014 in this subgroup is more realistic (note safer) than the date I proposed. The Phase 2b data in the Fall along with a licensing/partnership agreement with a company large enough to handle the U.S. roll-out will determine whether the FDA accepts such an early NDA filing.

Would Pharmasset consider signing a GT2/GT3 agreement for PSI-7977/SOC (exclusive of other genotypes) if early approval is in fact attainable?

I doubt it considering they want an experienced/well funded partner moving 7977/SOC into Phase 3 with the other genotypes. The possibility of an early filing increases the value of their asset substantially along with their leverage in doing a deal.